Answers are grounded in this paper and cite their sources.
Identifies specific biomarkers to differentiate thymic carcinoma from type B3 thymoma, suggesting improved diagnostic accuracy.
CD5 and CD117 are the best markers for TC. While the addition of other markers (i.e., BAP1 loss, MTAP loss and CDKN2A deletion) might be useful in cases negative for CD5 and CD117, rare cases of type B3 thymoma might harbor these alterations.
No takes yet. Share an insight, caveat, or question.
Poma et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: